Vernal keratoconjunctivitis market
Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, and Others), by Dosage Form (Gel, Ointment, Tablet, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
- Sep 2021
- CMI4657
- 321 Pages
- Excel & Pdf
- Pharmaceutical
Vernal keratoconjunctivitis (VKC) is an allergic eye disease. It is a multifactorial Th2 cell-mediated ocular surface inflammatory state that primarily affects males, specifically to children. Intense itching, burning, photophobia, and tears are the most common symptoms. The most common signs are conjunctival hyperaemia, superficial keratitis, and giant papillae. The overexpression of mast cells, Th2 cells, cytokines, eosinophils, adhesion molecules, chemokines, and cytokines are characteristics of the vernal keratoconjunctivitis. Limbal infiltration, corneal involvement, conjunctival fibroproliferative lesions, and conjunctival hyperemia are the features of vernal keratoconjunctivitis. Mixed, palpebral, and limbal are the three types of vernal keratoconjunctivitis, which are based on the main anatomical site of the papillary reaction.
The global vernal keratoconjunctivitis market is estimated to be valued at US$ 346.9 million in 2021 and is expected to exhibit a CAGR of 3.6% during the forecast period (2021-2028).
Figure 1.Global Vernal Keratoconjunctivitis Market Value (US$ million), By Region, 2021
Key players operating in the global vernal keratoconjuctivities market are focusing on drug approvals, which is anticipated to drive the market growth during the forecast period.
Increasing drug approvals provides the opportunity to provide patients with novel treatment options, which is projected to boost the market growth during the forecast period. For instance, in June 2021, Santen Pharmaceutical Co., Ltd. announced that U.S. Food and Drug Administration (FDA) approved a new drug verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children as well as adults.
Figure 2.Global Vernal Keratoconjuctivities Market Share (%) in Terms of Value, By Dosage Form, 2021
Growing incidences of vernal keratoconjuctivities in young adults and children living in warm environment, is estimated to spur the market growth during the forecast period.
Rising incidences of vernal keratoconjuctivities mainly in young adults and children living in warm environment, is anticipated to boost the market growth during the forecast period. In dark-skinned population from Africa and India, the limbal form of vernal keratoconjunctivities is seen most frequently. For instance, in August 2021, Western Europe incidences were 3.2 in 10,000, whereas in Italy, a country with a Mediterranean climate, a higher prevalence ranging from 2.4 to 27.8 in 10,000 were observed.
Vernal Keratoconjuctivities Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 346.9 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 3.6% | 2028 Value Projection: | US$ 443.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic
Several clinicians and patients requested better suggestion for the treatment of vernal keratoconjunctivities patients in the COVID-19 pandemic. Most of the patients and doctors were following the recommendations given by scientific societies such as Indian Journal of Ophthalmology. Recently, considering the various difficulties associated with the COVID-19 pandemic, despite the fact that patients require treatments, vernal keratoconjuctivitis has not been prioritised. Topical medicines are the primary line of treatment for types of vernal keratoconjuctivitis with topical corticosteroids added in severe cases of vernal keratoconjunctivitis, even in the patients are at risk of COVID-19.
Global Vernal Keratoconjunctivitis Market: Restraint
There is no precise diagnostic criteria for vernal keratoconjunctivitis, which is anticipated to hamper the market growth during the forecast period. The vernal keratoconjunctivitis disease's distinctive signs and symptoms are used to detect the diagnosis. Several mild or unusual instances may be undetected as no exact diagnostic criteria is been developed.
Key Players
Major players operating in the global vernal keratoconjunctivitis market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Treatment
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Brand Analysis
- Market Dynamics
- Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply and Demand Analysis
- Key Developments
- Global Vernal Keratoconjunctivitis Market, By Drug Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Bertilimumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Verkazia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Lodoxamide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antolimab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Nomacopan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Vernal Keratoconjunctivitis Market, By Treatment, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Mast Cell Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Topical Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Vernal Keratoconjunctivitis Market, By Dosage Form, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Gel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Ointment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Vernal Keratoconjunctivitis Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type , 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries/Region, 2017 – 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Santen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Senju Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allakos
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- iCo Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akari Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Santen
- Analyst Views
- Section
- Research Methodology
- About us
*Browse 30 market data tables and 36 figures on "Global Vernal Keratoconjunctivitis Market” - Global forecast to 2028